Upadacitinib Improves Giant Cell Arteritis in Phase 3 Trial ...Middle East

Results from the SELECT-GCA study showed upadacitinib (Rinvoq) induced significant and sustained remission in people with new-onset or relapsing giant cell arteritis. Medscape Medical News

Hence then, the article about upadacitinib improves giant cell arteritis in phase 3 trial was published today ( Friday 14/06/2024 - 01:53 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Upadacitinib Improves Giant Cell Arteritis in Phase 3 Trial )

Also on site :

• Walmart's 'Cute' $15 Beach Blanket Is Exactly What You Need for Outdoor Outings This Summer
• Russian officials inspect LNG tanker allegedly struck by Ukraine near Malta (VIDEO)
• Starbucks’ Korean sales fall after backlash to ‘Tank Day’ ad campaign